The 'In conversation with...' is a series of podcasts that will feature key figures from the life sciences sector speaking with National Horizons Centre staff about the issues affecting the industry.

Jason C. Foster from Oribiotech

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks to Jason Foster, CEO of Oribiotech, about how the pandemic has shone a light on the UK's life sciences sector and the important role of biotechnology, as well as what Oribiotech is doing regarding cell and gene therapy.

Nathalie Carter from NHS England

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks to Nathalie Carter, Darlington based Wellbeing & Stakeholder Relations Consultant; and Patient and Public Involvement Manager in the Innovation, Research and Life Sciences Group at NHS England. Discussion topics include what is next for the UK in the healthcare innovation space.

Nick Challoner from Croda

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks Nick Challoner, Chief Scientific Officer at speciality chemicals company Croda. Net Zero and how we can build back better are among the topics of discussion

Netty England and Kate Barclay

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks to Netty England, a Bioprocess Consultant and Kate Barclay, who is a Bioprocess Skills and Talent Consultant about how we can meet the demand for skills in the bioscience sector.

Pat McIver and Derek Willison-Parry from Lakes Biosciences

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks to Derek Willison-Parry, CEO of Lakes Biosciences, and Pat McIver, COO of Lakes Biosciences about the challenges facing the bioscience industry. In particular they look at how the North of England is best placed to expand the UK’s capabilities.

Kath Mackay from Alderley Park

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks to Kath Mackay, Managing Director of Alderley Park, a world-leading science and innovation park, about the challenges facing the bioscience sector.

Daria Donati from Cytiva

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks to Daria Donati, who is responsible for business development at life sciences company, Cytiva. Topics covered include the challenges the world faces in cell and gene therapy manufacturing.

Clive Dix from the Vaccines Task Force

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks to Clive Dix, chief executive of drug discovery company C4X Discovery who worked with the Vaccines Task Force for over a year, including five months as chair. The pair talk about the challenges that had to be overcome when developing a COVID-19 vaccine in less than 300 days.

Tees Valley Mayor Ben Houchen

Director of the National Horizons Centre, Dr Jen Vanderhoven, talks to Ben Houchen, Mayor of the Tees Valley, about how the COVID-19 pandemic has impacted the bioscience industry in the North East of England and future plans for the sector.

Dr Dave Tudor and Dr Lucy Foley from CPI

Director Dr Jen Vanderhoven speaks to Dr Dave Tudor, Managing Director of CPI's Medicines Manufacturing Innovation Centre, and Dr Lucy Foley, Director of Biologics at CPI. Topics covered include how the UK can respond to new variant threats of Covid-19 and how vaccines can be manufactured more quickly.

Paul Mines, Chair of the IBLF

Director Dr Jen Vanderhoven speaks with Paul Mines, chair of the Industrial Biotechnology Leadership Forum (IBLF) and CEO of Biome Bioplastics. Topics coved included how industrial biotechnology can improve sustainability and the future of industrial biotechnology.

Steve Bagshaw CBE

National Horizons Centre's Chief Industry Advisor Steve Bagshaw CBE gives his views on the UK's bio-manufacturing sector. Steve, who is the manufacturing lead on the UK Vaccines Taskforce and a former Chief Executive of FUJIFILM Diosynth Biotechnologies, speaks to the National Horizons Centre director Dr Jen Vanderhoven. Topics covered in the interview include the challenges face by the UK Vaccine's manufacturing industry and what the sector needs to do generate more capacity to meet the vaccine challenges of the future.

SIGN UP
TO OUR NEWSLETTER